title: Outcome of pediatric patients with lymphoma following stem cell transplant: a single institution report.
abstract: Hematopoietic stem cell transplant (HSCT) is recommended for pediatric patients with relapsed/refractory lymphoma even though the evidence for this is limited. We retrospectively reviewed records of 57 patients (29 Hodgkin lymphoma [HL], 28 non-Hodgkin lymphoma [NHL]) who underwent HSCT between 1995 and 2012. All demonstrated chemoresponsiveness prior to HSCT and 44 patients had a complete response. All underwent myeloablative conditioning, 38 chemotherapy-based and 19 total body irradiation-based. Forty-one patients received autologous and 16 allogeneic HSCT. Twelve (21%) died within 100 days post-HSCT, and 25 patients relapsed at a median of 1.6 months post-HSCT. Three patients developed second malignant neoplasms. Five-year overall survival (OS) was 50.5% and event-free survival (EFS) was 43.4%. Outcomes for HL were significantly better than those for NHL (OS 61.9% vs. 38.7% [p = 0.005] and EFS 60.4% vs. 26% [p = 0.008]). In summary, approximately half of all pediatric patients with lymphoma who failed first-line therapy and demonstrated chemosensitivity to second-line therapy can be salvaged with HSCT.
authors.affiliation: Department of Pediatric Hematology/Oncology, King Faisal Specialist Hospital & Research Center , Riyadh , Saudi Arabia.
authors.forename: Hassan
authors.initials: H
authors.lastname: Sumaili
authors.forename: Amani
authors.initials: A
authors.lastname: Al-Kofide
authors.forename: Amal
authors.initials: A
authors.lastname: Al-Seraihi
authors.forename: Mouhab
authors.initials: M
authors.lastname: Ayas
authors.forename: Khawar
authors.initials: K
authors.lastname: Siddiqui
authors.forename: Hassan
authors.initials: H
authors.lastname: El-Solh
authors.forename: Abdallah
authors.initials: A
authors.lastname: Al-Jefri
authors.forename: Ali
authors.initials: A
authors.lastname: Al-Ahmari
authors.forename: Amal
authors.initials: A
authors.lastname: Mohamed
authors.forename: Mohammed
authors.initials: M
authors.lastname: Anas
authors.forename: Asim F
authors.initials: AF
authors.lastname: Belgaumi
mesh_terms: D000293:Adolescent; D000367:Age Factors; D002648:Child; D002675:Child, Preschool; D018450:Disease Progression; D005260:Female; D006689:Hodgkin Disease / Q000175:diagnosis / Q000401:mortality / Q000628:therapy; D006801:Humans; D007223:Infant; D008223:Lymphoma / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D008228:Lymphoma, Non-Hodgkin / Q000175:diagnosis / Q000401:mortality / Q000628:therapy; D008297:Male; D009367:Neoplasm Staging; D011379:Prognosis; D012008:Recurrence; D033581:Stem Cell Transplantation / Q000379:methods; D016019:Survival Analysis; D016896:Treatment Outcome
keywords: Lymphoma; outcome; pediatrics; stem cell transplant